Amar Gajjar, MD
Disclosures: Nothing to disclose - 09/04/2022
OMB No. 0925-0046, Biographical Sketch Format Page

 

OMB No. 0925-0001 and 0925-0002 (Rev. 12/2020 Approved Through 02/28/2023)

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person.  DO NOT EXCEED FIVE PAGES.

NAME: GAJJAR, AMAR

eRA COMMONS USER NAME (credential, e.g., agency login): AGAJJAR

POSITION TITLE: Chair, Department of Pediatric Medicine

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

INSTITUTION AND LOCATION

DEGREE

(if applicable)

 

Completion Date

MM/YYYY

 

FIELD OF STUDY

 

Grant Medical College, J.J. Group of Hospitals, Bombay, India

MD

01/1982

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1. Personal Statement

I completed my pediatric Hematology and Oncology training and added an additional year of pediatric neuro-oncology training at St. Jude Children’s Research Hospital (SJCRH). Since joining the SJCRH faculty in 1993, my academic focus has been in pediatric neuro oncology. I have been an active participant in the NCI-funded national cooperative groups – Children’s Oncology Group (COG) and Pediatric Brain Tumor Consortium (PBTC) – since inception. I have been the PI of several clinical studies in the PBTC. At SJCRH, I Co-Lead the Neurobiology and Brain Tumor Program with Dr. Suzy Baker and have been the PI of several studies in the St. Jude Comprehensive Cancer Center (SJCCC). I have worked closely with Drs. Gilbertson, Roussel and Northcott to develop the translational and clinical program within the SJCCC. While improving cure rates is an important focus for patients that have a poor outcome, another key academic focus in my career is to reduce the long-term neurocognitive morbidities in patients that do have an excellent chance of survival. In order to accomplish this aim, I am the PI of 3 successive SJCRH-initiated collaborative medulloblastoma studies – SJMB96, SJMB03 and SJMB12. In each of these studies, we have refined the therapy of medulloblastoma by introducing novel therapy aimed at improving the cure rate while attempting to decrease the long-term neurotoxicity. I have led the clinical development of SMO inhibitors for SHH medulloblastoma. Our current front-line trial for medulloblastoma – SJMB12 is the first protocol that is treating medulloblastoma patients based on clinical and molecular risk. I am uniquely qualified to serve as a mentor for trainees and have an outstanding academic track record of mentoring trainees and publishing in high quality journals.

 

  1.    Gajjar A, Chintagumpala M, Ashley, D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St. Jude Medulloblastoma – 96): long-term results from a prospective, multicenter trial. Lancet Oncol, 7(10):797, 2006.
  2.    Merchant TE, Kun LE, Krasin MJ, Wallace D, Chintagumpala MM, Woo SY, Ashley DM, Sexton M, Kellie SJ, Ahern V, Gajjar A. A multi institutional prospective trial of reduced dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose- intensive chemotherapy for average-risk medulloblastoma. Int. J. Radiat Oncol Biol. Phys, 70(3):782–787, 2008. PMCID:  PMC2716663
  3.    Fouladi M, Chintagumpala M, Ashley D, Kellie S, Gururangan S, Hassall T, Gronewold L, Stewart CF, Wallace D, Broniscer A, Hale GA, Kasow K, Merchant TE, Morris B, Krasin M, Kun LE, Boyett JM, Gajjar A. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.  J Clin Oncol, 26(22):3749-3755, 2008. PMCID: PMC2504739
  4.    Stewart CF, Iacono LC, Chintagumpala M, Kellie SJ, Ashley D, Zamboni WC, Kirstein MN, Fouladi M, Seele

LG, Wallace D, Houghton PJ, Gajjar A.  Results of a phase II upfront window of pharmacokinetically guided

topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol, 22(16):3357-3365, 2004

  1.    Gajjar A, Stewart CF, Ellison DW, Kaste S, Kun LE, Packer RJ, Goldman S, Chintagumpala M, Wallace D, Takebe N, Boyett JM, Gilbertson RJ, Curran T. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a Pediatric Brain Tumor Consortium (PBTC) study. Clin Cancer Res, 19(22):6305-6312, 2013. PMCID: PMC3856244
  2.    Robinson GW, Rudneva VA, Buchhalter I, Billups CA, Waszak SM, Smith KS, Bowers DC, Bendel A, Fisher PG, Partap S, Crawford JR, Hassall T, Indelicato DJ, Boop F, Klimo P, Sabin ND, Patay Z, Merchant TE, Stewart CF, Orr BA, Korbel JO, Jones DTW, Sharma T, Lichter P, Kool M, Korshunov A, Pfister SM, Gilbertson RJ, Sanders RP, Onar-Thomas A, Ellison DW, Gajjar A (Senior Author),  Northcott PA. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol. 19(6):768-784, 2018. PMCID: PMC6078206
  3.    Gajjar A, Robinson GW, Smith KS, Lin T, Merchant TE, Chintagumpala M, Mahajan A, Su J, Bouffet E, Bartels U, Schechter T, Hassall T, Robertson T, Nicholls W, Gururangan S, Schroeder K, Sullivan M, Wheeler G, Hansford JR, Kellie SJ, McCowage G, Cohn R, Fisher MJ, Krasin MJ, Stewart CF, Broniscer A, Buchhalter I, Tatevossian RG, Orr BA, Neale G, Klimo P Jr., Boop F, Srinivasan A, Pfister SM, Gilbertson RJ, Thomas AO, Ellison DW, Northcott PA. Outcomes by Clinical and Molecular Features in Children with Medulloblastoma Treated with Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). J Clin Oncol. 39(7):822-835, 2021. PMID: 33405951

 

B.              Positions, Scientific Appointments, and Honors
 

1983 -

General Rotating Internship, Bombay University, Sir J.J. Group of Hospitals, Bombay

1984 - 1985

Research Fellow, University of Oklahoma, Department of Immunology, Oklahoma City, OK

1985 - 1986

Research Fellow, University of South Florida, Department of Pediatrics, St. Petersburg, FL

1986 - 1988

Pediatric Residency, USF, All Children's Hospital, St. Petersburg, FL

1988 - 1989

Chief Resident, USF, All Children's Hospital, St. Petersburg, FL

1989 -

Director Division of Neuro-Oncology, St. Jude Children's Research Hospital

1989 - 1992

Fellow, St. Jude Children's Research Hospital, Department of Hematology/Oncology, Memphis, TN

1992 - 1993

Fellow, St. Jude Children's Research Hospital, Division of Neuro-Oncology, Memphis, TN

1993 - 1999

Assistant Member, St. Jude Children's Research Hospital, Department of Hematology/Oncology, Memphis, TN

1993 - 2000

Assistant Professor, University of Tennessee, Memphis, College of Medicine, Memphis, TN

1999 - 2004

Associate Member, St. Jude Children's Research Hospital, Department of Hematology/Oncology, Memphis, TN

2000 -

Director, St. Jude Children's Research Hospital, Division of Neuro-Oncology, Department of Hematology/Oncology, Memphis, TN

2000 - 2005

Associate Professor, University of Tennessee, Memphis, College of Medicine, Memphis, TN

2004 -

Member, St. Jude Children's Research Hospital, Department of Hematology/Oncology, Memphis, TN

2005 -

Professor, Department of Pediatrics, University of Tennessee, College of Medicine, Memphis, TN

2005 -

Co-Leader, St. Jude Children's Research Hospital, Neurobiology and Brain Tumor Program, Memphis, TN

2006 -

Co-Chair, St. Jude Children's Research Hospital, Department of Oncology, Memphis, TN

2007 -

Scott and Tracie Hamilton Endowed Chair, St. Jude Children's Research Hospital, Division of Neuro-Oncology, Department of Oncology, Memphis, TN

2008 - 2009

Vice Chair, Children's Oncology Group, CNS Committee

2009 - 2018

Chair, Children's Oncology Group, CNS Committee

2013 2017

2017 – current 

Interim Chair, St. Jude Children's Research Hospital, Department of Pediatric Medicine

Chair, St. Jude Children’s Research Hospital, Department of Pediatric Medicine

 

 

  1. Contributions to Science


1.              My clinical research has focused on developing new treatment approaches for medulloblastoma that take into consideration the biology of the disease. To meet this objective, I have collaborated with a diverse group of faculty members in the Neurobiology and Brain Tumor Program in the St. Jude Comprehensive Cancer Center. My initial protocol (SJMB96) was an innovative study that used a shortened dose intensive course of chemotherapy following radiation therapy. For high risk patients with measurable disease – I devised a pharmacokinetically guided Topotecan window therapy – so as to test the efficacy of this agent in this disease setting. We published seminal findings that documented the neurocognitive deficits seen in this group of patients that were followed longitudinally. The successor protocol (SJMB03) was devised to further reduce the toxicity of therapy by reducing the volume of radiation therapy to the primary tumor as well as reducing the dose of Vincristine. We also collected fresh tumor tissue and blood for germ line DNA to explore the biology of medulloblastoma. These specimens were used in a whole genome sequencing project that uncovered the genetic aberrations in the 4 subgroups of medulloblastoma. The current study (SJMB 12) integrates the information from SJMB 96 and SJMB03 and has a novel treatment approach for all newly diagnosed patients according to clinical and molecular risk. SJMB12 has accrued more than 575 patients with medulloblastoma and based on the analysis from this study we are planning the next front line medulloblastoma study that will further refine therapy based on genomic classification based on methylation profiling.

 

  1.    Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon P, Wallace D, Lau C, Chintagumpala M, Ashley DM, Kellie SJ, Kun L, Gilbertson, RJ.  Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol, 22 (6):984-993, 2004
  2.    Stewart CF, Iacono LC, Chintagumpala M, Kellie SJ, Ashley D, Zamboni WC, Kirstein MN, Fouladi M, Seele LG, Wallace D, Houghton PJ, Gajjar A.  Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol, 22(16):3357-3365, 2004
  3.     Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol, 24(12):1924-1931, 2006
  4.    Gajjar AJ, Robinson GW. Medulloblastoma – translating discoveries from bench to bedside. Nat Rev Clin Oncol 11(11):714-722, 2014.
  5.    Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C, Groebner S, Grund KB, Brugières L, Jones DTW, Pajtler KW, Morrissy AS, Kool M, Sturm D, Chavez L, Ernst A, Brabetz S, Hain M, Zichner T, Segura-Wang M, Weischenfeldt J, Rausch T, Mardin BR, Zhou X, Baciu C, Lawerenz C, Chan JA, Varlet P, Guerrini-Rousseau L, Fults DW, Grajkowska W, Hauser P, Jabado N, Ra YS, Zitterbart K, Shringarpure SS, De La Vega FM, Bustamante CD, Ng HK, Perry A, MacDonald TJ, Hernáiz Driever P,  Bendel AE, Bowers DC, McCowage G, Chintagumpala MM, Cohn R, Hassall T, Fleischhack G, Eggen T, Wesenberg F, Feychting M, Lannering B, Schüz J, Johansen C, Andersen TV, Röösli M, Kuehni CE, Grotzer M, Kjaerheim K, Monoranu CM, Archer TC, Duke E, Pomeroy SL, Shelagh R, Frank S, Sumerauer D, Scheurlen W, Ryzhova MV, Milde T, Kratz CP, Samuel D, Zhang J, Solomon DA, Marra M, Eils R, Bartram CR, von Hoff K, Rutkowski S, Ramaswamy V, Gilbertson RJ, Korshunov A, Taylor MD, Lichter P, Malkin D, Gajjar A, Korbel JO, Pfister SM. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 19(6): 75-798, 2018. PMID: PMC5984248.
  6.      Robinson GW, Rudneva VA, Buchhalter I, Billups CA, Waszak SM, Smith KS, Bowers DC, Bendel A, Fisher PG, Partap S, Crawford JR, Hassall T, Indelicato DJ, Boop F, Klimo P, Sabin ND, Patay Z, Merchant TE, Stewart CF, Orr BA, Korbel JO, Jones DTW, Sharma T, Lichter P, Kool M, Korshunov A, Pfister SM, Gilbertson RJ, Sanders RP, Onar-Thomas A, Ellison DW, Gajjar A (Senior Author),  Northcott PA. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol. 19(6):768-784, 2018. PMCID: PMC6078206
  7.    Gajjar A, Robinson GW, Smith KS, Lin T, Merchant TE, Chintagumpala M, Mahajan A, Su J, Bouffet E, Bartels U, Schechter T, Hassall T, Robertson T, Nicholls W, Gururangan S, Schroeder K, Sullivan M, Wheeler G, Hansford JR, Kellie SJ, McCowage G, Cohn R, Fisher MJ, Krasin MJ, Stewart CF, Broniscer A, Buchhalter I, Tatevossian RG, Orr BA, Neale G, Klimo P Jr., Boop F, Srinivasan A, Pfister SM, Gilbertson RJ, Thomas AO, Ellison DW, Northcott PA. Outcomes by Clinical and Molecular Features in Children with Medulloblastoma Treated with Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). J Clin Oncol. 39(7):822-835, 2021. PMID: 33405951

 

  1.    Kumar R, Smith KS, Deng M, Terhune C, Robinson GW, Orr BA, Liu APY, Lin T, Billups CA, Chintagumpala M, Bowers DC, Hassall TE, Hansford JR, Khuong-Quang DA, Crawford JR, Bendel AE, Gururangan S, Schroeder K, Bouffet E, Bartels U, Fisher MJ, Cohn R, Partap S, Kellie SJ, McCowage G, Paulino AC, Rutkowski S, Fleischhack G, Dhall G, Klesse LJ, Leary S, Nazarian J, Kool M, Wesseling P, Ryzhova M, Zheludkova O, Golanov AV, McLendon RE, Packer RJ, Dunham C, Hukin J, Fouladi M, Faria CC, Pimentel J, Walter AW, Jabado N, Cho YJ, Perreault S, Croul SE, Zapotocky M, Hawkins C, Tabori U, Taylor MD, Pfister SM, Klimo P Jr, Boop FA, Ellison DW, Merchant TE, Onar-Thomas A, Korshunov A, Jones DTW, Gajjar A, Ramaswamy V, Northcott PA. Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. J Clin Oncol. 39(7):807-821, 2021. PMID: 33502920

 

  1. I have focused my clinical research on development of novel agents for therapy of brain tumors in childhood. I have been the PI for several Phase I and Phase II protocols that have sought to define the efficacy and toxicity of conventional chemotherapy agents and molecular targeted therapies against a wide variety of pediatric brain tumors. More recently I have collaborated closely with Dr Gilbertson and Dr Roussel in conducting high throughput screening with libraries of FDA approved compounds to repurpose “hits” from the screens to test against relevant brain tumors. I have led the development of SMO inhibitors in SHH medulloblastoma – these clinical protocols have identified a subgroup of medulloblastoma with PTCH and SMO mutations that are most likely to respond to this class of drugs. Based on these protocols we currently treating newly diagnosed SHH subgroup patients with SMO inhibitors.

 

  1.    Gajjar A, Chintagumpala MM, Bowers DC, Jones-Wallace D, Stewart CFS, Crews KR. Effect of Intra-patient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy. Cancer, 97(9 Suppl):2374-2380, 2003.
  2.    Broniscer A, Baker SJ, Stewart CF, Merchant TE, Laningham FH, Schaiquevich P, Kocak M, Morris B, Endersby R, Ellison DW, Gajjar A. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents and young adults with high-grade glioma. Clin Cancer Res, 15(2):701-707, 2009. PMCID:  PMC2629527
  3.     Morfouace M, Shelat A, Jacus M, Freeman BB, Turner D, Robinson S, Zindy F, Wang M, Finkelstein D,  Ayrault O, Bihannic L, Robinson G, Li XN, Guy K, Stewart C, Gajjar A Rousse MF. Repurposing pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.  Cancer Cell, 25(4):516-29, 2014. PMCID: PMC3994669
  4.    Gajjar A, Stewart CF, Ellison DW, Kaste S, Kun LE, Packer RJ, Goldman S, Chintagumpala M, Wallace D, Takebe N, Boyett JM, Gilbertson RJ, Curran T. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a Pediatric Brain Tumor Consortium (PBTC) study. Clin Cancer Res, 19(22):6305-6312, 2013. PMCID: PMC3856244
  5.    Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer R, Goldman S, Prados M, Desjardins A, Chintagumpala M,  Tabeke N, Rusch M, Gupta P, Thrasher A, Allen SJ, Li S, Stewart CF, Fouladi M, Boyett JM, Curran T, Gilbertson RJ, Ellison DW, Gajjar A. Vismodegib shows efficacy against recurrent SHH subtype medulloblastoma: Results of two phase II Pediatric Brain Tumor Consortium Studies – PBTC-025B & PBTC-032. J Clin Oncol 33(24):2646-2654, 2015. PMCID: PMC4534527
  6.      Robinson GW, Kaste SC, Chemaitilly W, Bowers DC, Laughton S, Smith A, Gottardo NG, Partap S, Bendel A, Wright KD, Orr BA, Warner WC, Onar-Thomas A, Gajjar A. Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. Oncotarget. 8(41):69295-69302, 2017. PMID: 29050204
  7.    Wright KD, Daryani VM, Turner DC, Onar-Thomas A, Boulos N, Orr BA, Gilbertson RJ, Stewart CF, Gajjar A. Phase 1 study of 5-fluorouracil in children and young adults with recurrent ependymoma. Neuro Oncol 17(12):1620-1627, 2015. PMCID: PMC4633933
  8.    Levy AS, Krailo M, Chi S, Villaluna D, Springer L, Williams-Hughes C, Fouladi M, Gajjar A.

Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial. Pediatr Blood Cancer. 2021 Apr 12;e29031. Online ahead of print. PMID: 33844469

 

  1. Studying the late effects of CNS directed therapy has been another research focus. Studying and documenting the last morbidities of therapy has led to strategies that attempt mitigate long term side effects, particularly in young children treated with multimodality therapy that includes surgery, chemotherapy, and radiation therapy. The younger the age of the child there is increased risk of late effects including development of subsequent malignancies.
    1. Laughton SJ, Merchant TE, Sklar CA, Kun LE, Fouladi M, Broniscer A, Morris EB, Sanders RP, Krasin MJ, Shelso J, Xiong Z, Wallace D, Gajjar A.  Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary site irradiation and high-dose chemotherapy with stem cell rescue on the SJMB-96 trial. J Clin Oncol 26(7):1112-1118, 2008.
    2. Fouladi M, Chintagumpala M, Ashley D, Kellie S, Gururangan S, Hassall T, Gronewold L, Stewart CF, Wallace D, Broniscer A, Hale GA, Kasow K, Merchant TE, Morris B, Krasin M, Kun LE, Boyett JM, Gajjar A. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.  J Clin Oncol 26(22):3749-3755, 2008. PMCID: PMC2504739
    3. Palmer SL, Hassall, T, Evankovich, K, Mabbott DJ, Bonner M, Deluca C, Cohn R, Fisher MJ, Morris EB, Broniscer A, Gajjar A. Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with embryonal tumors. Neuro Oncol 12(12):1311-1317, 2010. PMCID: PMC3018935
    4. Brinkman T, Palmer SL, Chen S, Zhang H, Evankovich K, Swain MA, Bonner MJ, Janzen L, Knight S, Armstrong CL, Boyle R, Gajjar A. Parent-reported social outcomes after treatment for pediatric embryonal tumors: a prospective longitudinal study. J Clin Oncol 30(33):4134-4140, 2012. PMCID: PMC23071220
    5. Palmer SL, Armstrong C, Onar-Thomas A, Wu S, Wallace D, Bonner MJ, Schreiber J, Swain M, Chapieski L, Mabbott D, Knight S, Boyle R, Gajjar A. Processing speed, attention and working memory after treatment for medulloblastoma: An international, prospective and longitudinal study. J Clin Oncol 31(28):3494-3500, 2013. PMCID: PMC3782147
    6. Gurney JG, Bass JK, Onar-Thomas A, Huang J, Chintagumpala M, Bouffet E, Hassall T, Gururangan S, Heath JA, Kellie S, Cohn R, Fisher MJ, Pai Panandiker A, Merchant TE, Srinivasan A, Wetmore C, Qaddoumi I, Stewart CF, Armstrong GT, Broniscer A, Gajjar A. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average risk or high risk medulloblastoma. Neuro Oncol 16(6):848-855, 2014. PMCID: PMC4022215
    7. Palmer SL, Leigh L, Ellison SC, Onar-Thomas A, Wu S, Qaddoumi I, Armstrong GT, Wright K, Wetmore C, Broniscer A, Gajjar A. Feasibility and efficacy of a computer-based intervention aimed at preventing reading decoding deficits among children undergoing active treatment for medulloblastoma: results of a randomized trial. J. Pediatr Psychol 39(4):450-458, 2014. PMCID: PMC3994317
    8. Schreiber JE, Gurney JG, Palmer SL, Bass JK, Wang M, Chen S, Zhang H, Swain M, Chapieski ML, Bonner ML, Mabbott DJ, Knight S, Armstrong CL, Boyle R, Gajjar A. Examination of risk factors for intellectual and academic outcomes following treatment for pediatric medulloblastoma. Neuro Oncol 16(8):1129-1136, 2014. PMCID: PMC4096173
    9. Knight SJ, Conklin HM, Palmer SL, Schreiber JE, Armstrong CL, Wallace D, Bonner B, Swain MA, Evankovich KD, Mabbott DJ, Boyle R, Huang Q , Zhang H, Anderson VA, Gajjar A. Working memory abilities among children treated for medulloblastoma. J Pediatr Psycho 39(5):501-511, 2014. PMCID: PMC4027880
    10. Merchant TE, Schreiber J, Wu S, Lukose R, Xiong X, Gajjar A. Critical combinations of radiation dose and volume predict IQ and academic achievement scores after craniospinal irradiation in    children with medulloblastoma. Int J Radiat Oncol Biol Phys 90(3):554-561, 2014. PMCID:    PMC4703579.
    11. DeWire M, Green DM, Sklar CA, Merchant TE, Wallace D, Lin T, Vern-Gross T, Kun LE, Krasin MJ, Boyett JM, Wright KD, Wetmore CJ, Broniscer A, Gajjar A. Pubertal development and ovarian dysfunction in survivors of embryonal brain tumors following risk- adapted craniospinal irradiation and adjuvant chemotherapy. Pediatr Blood Cancer. 62(2):329-334, 2015. PMCID: PMC4402092
    12. Tsui K, Gajjar A, Li C, Srivastava D, Broniscer A, Wetmore C, Kun LE, Merchant TE, Ellison DW, Orr BA, Boop FA, Klimo PA, Ross JD, Robison LL, Armstrong GT. Subsequent neoplasms in survivors of childhood central nervous system tumors: Risk after modern, multi-modal therapy. Neuro Oncol 17(3):448-456, 2015. PMCID: PMC4483102
    13. Schreiber JE, Palmer SL, Conklin HM, Mabbott DJ, Swain M, Bonner MJ, Chapieski ML, Huang L, Zhang H, Gajjar A. Posterior fossa syndrome and long-term neurobehavioral problems among children treated for medulloblastoma on a multi-institutional, prospective study. Neuro Oncol. 19(12):1673-1682, 2017.  PMCID: PMC5716082
    14. Jacola LM, Anghelescu DL, Hall L, Russell K, Zhang H, Wang F, Peters JB, Rossi M, Schreiber JE, Gajjar A. Anesthesia Exposure During Therapy Predicts Neurocognitive Outcomes in Survivors of Childhood Medulloblastoma. J Pediatr. 223:141-147.e4, 2020. PMCID: PMC7387137
    15. Ali JS, Ashford J, Swain MA, Harder LL, Carlson-Green BL, Miller JM, Wallace J, Kaner RJ, Billups CA, Onar-Thomas A, Merchant TE, Gajjar A, Conklin HM. Predictors of Cognitive Performance among Infants Treated for Brain Tumors: Findings from a Multisite, Prospective, Longitudinal Trial. J Clin Oncol. 2021 May 4: DOI https://doi.org/10.1200/JCO.20.01687

Complete List of Published Work in My Bibliography:
http://www.ncbi.nlm.nih.gov/myncbi/amar.gajjar.1/bibliography/43927661/public/?sort=date&direction=ascending